EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access

Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study

Oscar Hou-In Chou, Zhiyao Luo iD, Cheuk To Skylar Chung iD, Jeffrey Chan iD, Huixian Li, Ishan Lakhani iD, Sharen Lee iD, Dawnie Ho Hei Lau, Qingpeng Zhang iD, Tong Liu iD, Wing Tak Wong iD, Bernard Man Yung Cheung iD und 4 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.123.034175 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Oscar Hou-In Chou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Peripheral Arterial Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is), dipeptidyl peptidase‐4 inhibitors (DPP4Is), and glucagon‐like peptide‐1 receptor agonists have been associated with improved cardiovascular outcomes and prognosis. The comparative risks of new‐onset peripheral artery disease (PAD) between these medications remain unknown. This real‐world study compared the risks of PAD in patients exposed to SGLT2I and DPP4I. METHODS AND RESULTS This was a retrospective population‐based cohort study of patients with type 2 diabetes on either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2015, using a territory‐wide database from Hong Kong. The primary outcome was new‐onset PAD. The secondary outcomes were cardiovascular hospitalization, cardiovascular death, and all‐cause death. Propensity score matching (1:1 ratio) using the nearest neighbor search was performed. Multivariable Cox regression with time‐weighted variables was used to identify significant associations. A 3‐arm analysis including the glucagon‐like peptide‐1 receptor agonist cohort was conducted. This cohort included 75 470 patients with type 2 diabetes (median age, 62.3±12.8 years; 55.79% men). The SGLT2I and DPP4I groups consisted of 28 753 patients and 46 717 patients, respectively. After matching, 186 and 256 patients had PAD in the SGLT2I and DPP4I groups, respectively, over a median follow‐up of 5.6 years. SGLT2I use was associated with lower risks of PAD (hazard ratio [HR], 0.79 [95% CI, 0.66–0.93]) compared with DPP4I use after adjusting for demographics, comorbidities, medications, renal function, and glycemic tests. The association remained consistent regardless of sex, age, and other metabolic diseases. In the 3‐arm analysis, the risk of PAD was not statistically different between SGLT2Is and glucagon‐like peptide‐1 receptor agonists (HR, 1.18 [95% CI, 0.52–2.68]). The results remained consistent in the competing risk and the sensitivity analyses.

Conclusions

SGLT2I use among patients with type 2 diabetes was associated with lower risks of new‐onset PAD and PAD‐related outcomes when compared with DPP4Is after adjustments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsPeripheral Arterial DiseaseGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedHong KongRisk FactorsRisk AssessmentTreatment OutcomeTime FactorsIncidence

Stichwörter der Autor:innen

amputationcardiovascular diseasedipeptidyl peptidase‐4 inhibitorsglucagon‐like peptide‐1 receptor agonistsperipheral artery diseasesodium‐glucose cotransporter‐2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China.
  • Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong China.
  • Institute of Biomedical Engineering, Department of Engineering Science University of Oxford Oxford UK.
  • School of Life Sciences Chinese University of Hong Kong Hong Kong China.
  • Musketeers Foundation Institute of Data Science and Department of Pharmacology and Pharmacy, LKS Faculty of Medicine The University of Hong Kong Hong Kong China.
  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China.

ORCID-Profile: Zhiyao Luo, Cheuk To Skylar Chung, Jeffrey Chan, Ishan Lakhani, Sharen Lee, Qingpeng Zhang, Tong Liu, Wing Tak Wong, Bernard Man Yung Cheung, Gregory Y H Lip, Gary Tse, Jiandong Zhou

Zitieren

APA

Chou, O. H., Luo, Z., Chung, C. T. S., Chan, J., Li, H., Lakhani, I., Lee, S., Lau, D. H. H., Zhang, Q., Liu, T., Wong, W. T., Cheung, B. M. Y., Lip, G. Y. H., Leung, F. P., Tse, G., & Zhou, J. (2025). Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.034175

Vancouver

Chou OH, Luo Z, Chung CTS, Chan J, Li H, Lakhani I, et al. Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.123.034175

BibTeX
@article{Chou2025,
  author = {Chou, Oscar Hou-In and Luo, Zhiyao and Chung, Cheuk To Skylar and Chan, Jeffrey and Li, Huixian and Lakhani, Ishan and Lee, Sharen and Lau, Dawnie Ho Hei and Zhang, Qingpeng and Liu, Tong and Wong, Wing Tak and Cheung, Bernard Man Yung and Lip, Gregory Y H and Leung, Fung Ping and Tse, Gary and Zhou, Jiandong},
  title = {Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.123.034175}
}
Kostenlos starten →